Project Grant K99CA304360
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$170K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
The U.S. Department of Defense's Defense Health Agency awarded a $526,042 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to support research aimed at identifying and targeting mechanisms of prostate cancer therapy resistance driven by the tumor microenvironment. The project will be conducted over a 2-year period from May 1, 2024 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). This research grant...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research aimed at overcoming resistance to radiopharmaceutical therapy (RPT) in prostate cancer. The $404,972 award, effective August 1, 2025 through July 31, 2027, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how the tumor microenvironment, specifically the enzyme ENPP1, can limit the immune-activating effects of PSMA-targeted RPT....
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Fred Hutchinson Cancer Center in Seattle, WA to define how natural killer (NK) cells regulate the tumor microenvironment and enhance anti-tumor immune responses. The research aims to: Determine tumor-intrinsic features that regulate NK cell phenotype and function in the tumor; Define the mechanisms that regulate NK cell production of...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
This Project Grant award of $139,184 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research by the Fred Hutchinson Cancer Center in Seattle, Washington to investigate the role of RNA components of the translation apparatus in prostate cancer plasticity and therapy resistance. The research aims to elucidate how a specific tRNA, ARG-TCT-1-1, impacts lineage plasticity in prostate cancer, and determine the mechanisms by which 5' UTR-specific mRNA...